Technologies
PDF


WARF: P150214US02

Nylon-3 Polymers Active Against Clostridium Difficile


INVENTORS -

Samuel Gellman, Runhui Liu, Bernard Weisblum, Shonna McBride

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing nylon-3 polymers to treat and prevent C. difficile infections via oral therapeutic or disinfectant formulations.
OVERVIEWClostridium difficile is a Gram-positive, endospore-forming anaerobe that causes life-threatening intestinal infections. These infections result in more than 14,000 deaths and billions of dollars in healthcare costs every year in the U.S. alone. The bacteria can survive as dormant spores outside of a host and, once ingested, germinate into toxic vegetative cells.

C. difficile has been listed by the CDC as the highest level threat of antibiotic resistance in the nation. Current treatment consists of metronidazole, vancomycin or, most recently, fidaxomicin. Unfortunately these antibiotics are not always effective and recurrence of disease occurs in many patients.

To combat this escalating challenge, new treatment strategies are being explored. Synthetic polymers that mimic the natural antimicrobial properties of host-defense peptides are one promising, cost-effective solution.
THE INVENTIONUW–Madison researchers and collaborators at Emory Medical School have developed nylon-3 polymers and copolymers active against C. difficile. The polymers have been shown to inhibit outgrowth/growth of the bacteria in spore and vegetative form.
APPLICATIONS
  • Therapeutic agents to treat and prevent C. difficile infections
  • Oral formulation
  • Surface treatment (disinfectant)
KEY BENEFITS
  • New treatment option against deadly, drug-resistant bacteria
  • Outperform front-line drug vancomycin at inhibiting spore outgrowth
  • Cheaper to synthesize than peptides
  • Able to resist proteolytic degradation
STAGE OF DEVELOPMENTThe surface treatment application will likely need additional testing to support efficacy claims and consumer safety requirements.

The therapeutic antibiotic treatment will require preclinical and clinical testing to support regulatory approval, but legislation recently introduced in congress (Promise for Antibiotics and Therapeutics for Health Act, 2014) may accelerate FDA approval.
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Liu R., Suarez J.M., Weisblum B., Gellman S.H. and McBride S.M. 2014. Synthetic Polymers Active Against Clostridium difficile Vegetative Cell Growth and Spore Outgrowth. J. Am. Chem. Soc. 136, 14498.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.